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Abstract 
Background: The prevalence and incidence of chronic conditions, such as pain and opioid dependence, have 
implications for policy development, resource allocation and healthcare delivery.  The primary objective of 
the current review was to estimate the incidence of iatrogenic opioid dependence or abuse following 
treatment with opioid analgesics. 
Methods: Systematic electronic searches utilised six research databases (Embase, Medline, PubMed, Cinahl 
Plus, Web of Science, OpenGrey).  A ‘grey’ literature search and a reference search of included articles were 
also undertaken.  The PICOS framework was used to develop search strategies and the findings are reported 
in accordance with the PRISMA Statement. 
Results:  Following eligibility reviews of 6164 articles, 12 studies (involving 310,408 participants) were 
retained for inclusion in the meta-analyses.  A random effects model (DerSimonian-Laird method) generated 
a pooled incidence of opioid dependence or abuse of 4.7%.  There was little within-study risk of bias and no 
significant publication bias; however, substantial heterogeneity was found among study effects (99.78%).  
Sensitivity analyses indicated that the diagnostic criteria selected for identifying opioid dependence or abuse 
(DSM-IV versus ICD-9) accounted for 20% and duration of exposure to opioid analgesics accounted for 18% 
of variance in study effects. Longer-term opioid analgesic exposure, and prescription of strong rather than 
weak opioids, were associated with a significantly lower incidence of opioid dependence or abuse. 
Conclusions: The incidence of iatrogenic opioid dependence or abuse was 4.7% of those prescribed opioids 
for pain.  Further research is required to confirm the potential for our findings to inform prevention of this 
serious adverse event. 
 
Keywords: Analgesics, opioid; Incidence; Opioid-related disorders; Pain. 
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Introduction 
Rationale 
The prevalence and incidence of chronic, relapsing conditions, such as chronic pain, have implications for 
policy development, resource allocation and healthcare delivery.  Physical dependence and addiction are 
major clinical concerns that may deter adequate analgesic prescribing for patients whose previous treatment 
regimens have proven unsuccessful.  Abuse and diversion of these drugs is an increasing problem that has 
been associated with increased prescribing rates1; however, there is little robust scientific evidence 
concerning the incidence of iatrogenic dependence disorders associated with opioid analgesic therapy.  
Indeed, there is growing interest2 in the phenomenon of ‘pseudoaddiction’, an “iatrogenic syndrome that 
mimics the behavioural symptoms of addiction” in patients receiving inadequate analgesia3.  This growing 
interested was highlighted in a systematic review examining the ‘footprint’ of pseudoaddiction in the 
literature2; however, it concluded that, to date, there is insufficient evidence to support or refute the 
existence of this phenomenon. 
 
As the current review highlights, there is a dearth of prospective data examining de novo incidence of opioid 
misuse following analgesic prescribing; however this issue has been examined retrospectively4 5.  These 
studies are limited, however, by an inability to establish the relative onset of chronic pain and opioid 
dependence.  Patients are likely to seek analgesic treatment at an early stage in the development of pain, 
because it is perceived as problematic immediately following onset.  Treatment for opioid dependence, 
however, is likely to be sought at a relatively later stage in disease development, because it is often not 
perceived as ‘problematic’ until symptoms become unmanageable.  Additional issues arise due to the vague, 
and frequently changing, definitions associated with terms such as ‘addiction’ – a ubiquitous term in the 
literature which has been used synonymously with ‘dependence’ or with the wider definition of ‘abuse’, or, 
synonymously as an umbrella term, with ‘aberrant drug-related behaviour’. 
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Several reviews have examined the relationship between opioid analgesic prescribing and opioid misuse6 7 8 
9 10; however, many examined prevalence (existing cases) – rather than incidence (new cases) – and, in 
consequence, were unable to conclude that dependence or abuse was a direct function of opioid analgesic 
treatment.  Furthermore, since studies included in many of these reviews were unable to control for pre-trial 
substance misuse, findings may reflect prevalence – rather than incidence – and, therefore, may not reflect 
a truly iatrogenic phenomenon. 
 
Whilst the physiological characteristics of acute dependence are anticipated following prolonged exposure 
to opioids, clinical diagnoses of opioid dependence or abuse disorders are not.  Acute tolerance is 
demonstrated to occur several minutes or hours following exposure11; however, dependence associated with 
prolonged exposure has not be characterised.  Some studies have suggested that the proposed 7 days12 has 
not been challenged adequately and remains a valid threshold13 whilst other studies have used a more 
cautious approach to ensure that there is no controversy – for example, 2 weeks14, 1 month15 or 3 months16. 
 
The development of addiction-related problems is influenced by numerous factors and, as such, cannot be 
considered to be a direct function solely of opioid prescribing; however, the iatrogenic component is of key 
concern to both policy-makers and practitioners.  Whilst it is important to acknowledge that a number of 
reviews have examined this topic, as recently as 2015, their translational value has been restricted by two 
important limitations.  First, a wide range of addiction-related outcomes have been addressed without their 
having been defined clearly in these reviews and/or in included articles.  This limits the potential for pooling 
homogenous study findings.  Secondly, addressing prevalence (existing cases) – rather than incidence (new 
cases) – prevents control of pre-existing addiction-related problems.  Such an examination of prevalence 
would, therefore, result in the inclusion of participants whose pre-existing drug-seeking behaviour led them 
to seek opioid analgesic treatment.  Whilst information concerning the prevalence of addiction-related 
problems in patients in receipt of opioid analgesics is relevant, in terms of resource allocation, it does not 
permit elucidation on opioid dependence or abuse as an iatrogenic syndrome.  The present review is 
distinguished from previous reviews in that it: (1) focuses on clinically-diagnostic opioid dependence or abuse 
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as the outcome, rather than on a poorly-defined range of addiction-related terminology; and (2) examines 
incidence (new cases) – rather than prevalence (existing cases) – of opioid dependence or abuse following 
analgesic treatment, thereby facilitating an understanding of the contributory role of opioid analgesic 
prescribing on the subsequent development of dependence and abuse disorders. 
 
Objective 
The primary objective of the current review was to generate a pooled estimate of the incidence of iatrogenic 
opioid dependence or abuse in patients with pain who were exposed to opioid analgesic therapy, based on 
a systematic review of published studies.  It was hoped that data concerning dependence and abuse would 
be provided separately; however, it was anticipated that this distinction probably could not be made in 
studies.  In the absence of distinct data for these two disorders, it was decided that data for these disorders 
would be pooled to provide an indication of a clinical dependence/abuse disorder.  Should substantial 
heterogeneity be identified, sensitivity analyses would be undertaken in an effort to describe variance in 
study effects. 
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Methods 
The established PICOS framework (Population, Interventions, Comparators, Outcomes and Study design) was 
used to design the review and to develop an appropriate search strategy.  The findings are reported in 
accordance with the recommendations set out in the Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses (PRISMA)17 (Appendix 1).  The structure of the current paper is based on the PRISMA 27-item 
checklist.  The PRISMA four-phase flow diagram was used to show eligibility screening procedures (Figure 1). 
 
Protocol and registration 
The review protocol was registered on PROSPERO, the international database of prospectively registered 
systematic reviews in health and other related domains of study.  The protocol registration number is 
CRD42017058445 and can be accessed at { HYPERLINK 
"https://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42017058445" }. 
 
Eligibility criteria 
Populations were included if they were patients with pain in receipt of opioid analgesic treatment.  Animal 
and in vitro models were excluded. 
Interventions took the form of opioid analgesic treatment for a sufficient length of time for dependence to 
develop potentially.  This is, of course, dependent upon a number of complex drug- and patient-related 
characteristics and the time between exposure and the development of dependence has not yet been 
characterised in humans.  Data were, therefore, extracted from all studies where participants were exposed 
to opioid analgesics for 7 days or more and sensitivity analyses were undertaken based on the conservative 
exposure threshold of 3 months’ exposure.  Studies were excluded if they focused on opioid exposure in 
patients in receipt of opioid replacement therapy (ORT) for the treatment of opioid dependence. 
Comparator populations were not applicable in the current review. 
Outcomes comprised incidence from studies that specified a clinical diagnosis of opioid dependence or abuse 
disorder (established in studies by employing the use of DSM/ICD criteria or by clinician assessment).  Studies 
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were excluded if they reported prevalence (existing cases) – rather than incidence (new cases) – to ensure 
that cases with pre-existing substance use disorders were not included in the pooled summary statistic.  
Studies were also excluded if they relied upon patient reports or proxy indicators of opioid misuse since it is 
impossible, using these methods of data collection, to distinguish between clinically-diagnostic dependence 
or abuse disorders and the wider concepts associated with ‘addiction’.  Articles using the terms ‘addiction’, 
‘misuse’ and ‘abuse’ were included if these terms represented a clinical diagnosis of opioid dependence or 
abuse disorder, identified either using DSM/ICD criteria or by clinician assessment. 
Study designs that were excluded were case reports (since 0% or 100% incidence would not be meaningful 
within the context of meta-analysis) or presenting secondary data (to avoid duplication of articles presenting 
primary data). 
 
Information sources 
Electronic searches were undertaken using: Embase; Medline; PubMed; Cinahl Plus; Web of Science and 
OpenGrey.  A ‘grey’ literature search and a manual search of the references of included publications was also 
undertaken. 
 
Search 
The search term was constructed using the PICOS principles, shown below, and was run in each of the 
electronic databases.  Searches were run on 1 April and no date restrictions were applied.  The English 
language filter was applied in all databases and the participants filter (human only) was applied where 
available (Embase, Medline and PubMed). 
 
Population: pain 
Intervention: opioid* OR opiate* OR buprenorphine OR codeine OR diamorphine OR dihydrocodeine OR 
dipipanone OR fentanyl OR hydromorphone OR meptazinol OR methadone OR morphine OR oxycodone OR 
papaveretum OR pentazocine OR pethidine OR tramadol OR tapentadol OR levorphanol OR oxymorphone 
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OR meperidine OR butorphanol OR opium OR propoxyphene OR alfentanil OR levomethadyl OR sufentanil 
OR remifentanil OR dextropropoxyphene OR ketobemidone 
Comparators: Not included in search strategy 
Outcomes: (depend* OR toleran* OR withdraw*) AND (prevalence OR incidence OR rate* OR frequenc* OR 
proportion* OR percent*) 
Study design: Not included in search strategy 
 
Study selection 
Initially, articles underwent title and abstract review.  Where articles clearly did not meet inclusion criteria, 
they were excluded, and the reason for exclusion was recorded.  Remaining articles underwent full text 
eligibility review, in light of careful consideration of the inclusion and exclusion criteria, and the reason for 
each article excluded at this stage was recorded.  A random selection of 25% of included articles was assessed 
by a second reviewer who was blind to title, author, journal and year of publication. 
 
Data collection process 
A data extraction proforma was designed and piloted with 5 of the included articles.  Where required, authors 
were contacted in an effort to seek clarification on the data presented in articles. 
 
Data items 
Data items were extracted and recorded on a pre-piloted proforma.  The data items that were extracted for 
each study (where available) were: author(s); article title; date of publication; study design; number recruited 
and final number included in sample; pain type (malignant or non-malignant); nature of pain (nociceptive or 
neuropathic); name of opioid analgesic(s) (used to identify strong and weak opioids); length of exposure to 
opioid analgesic; method for diagnosing opioid dependence disorder (DSM, ICD or clinician assessment); 
event rate (total population under investigation and number of events reported); subgroup data (event rate 
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for all subgroups, as described in ‘Additional Analyses’); and additional notes (free text box in which 
explanatory notes or issues for consideration were recorded). 
 
Risk of bias in individual studies 
Assessment of risk of bias in individual studies was undertaken at study level.  Study design was identified 
using Agency for Healthcare Research and Quality AHRQ (US DoH) criteria18.  Risk of bias assessment was 
achieved using instruments designed by the National Institutes of Health (NIH).  Two instruments were 
required for use in the current review: 
1. Quality Assessment Tool for Before-After (Pre-Post) Studies with No Control Group (URL: { 
HYPERLINK "https://www.nhlbi.nih.gov/health-pro/guidelines/in-develop/cardiovascular-risk-
reduction/tools/before-after" }) 
2. Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies (URL: { HYPERLINK 
"https://www.nhlbi.nih.gov/health-pro/guidelines/in-develop/cardiovascular-risk-
reduction/tools/cohort" }) 
These instruments are not intended to be summed to provide a total score, since assigning scores may be 
considered to be misleading19.  Instead, these instruments are designed to prompt consideration of the key 
concepts relating to internal validity and potential risk of bias in individual study designs.  As such, study 
quality was rated as: ‘poor’; ‘fair’; or ‘good’. 
 
Summary measures 
The principal measure used was event rate – i.e. the proportion of total population developing dependence 
or abuse.  The raw event rate was shown in forest plots and reported as percentages in the main body of the 
text. 
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Synthesis of results 
Pooled incidence estimates were generated using the random effects (DerSimonian-Laird method) model.  
Individual studies were weighted in accordance with the principle of inverse variance and, since a random 
effects model was applied, this included between-study variance in addition to within-study variance.  
Several measures of heterogeneity have been reported (Cochran’s Q; Tau2; and I2); however, the preferred 
I2 statistic20 was discussed in the text.  Definitive heterogeneity thresholds can be misleading; however, as 
per guidance in the Cochrane Handbook (section 9.5.2) we accepted that ≥50% may represent substantial 
heterogeneity. 
 
Risk of bias across studies 
Publication bias was assessed using the Egger regression intercept and the Begg-Mazumdar rank correlation 
test.  The use of imputational strategies in meta-analyses remain controversial and, furthermore, are unlikely 
to alter the conclusions in over 90% of secondary data analyses21.  In consequence, imputational strategies 
were not used in the current review. 
 
Additional analyses 
Sensitivity analyses were undertaken in an effort to explain substantial heterogeneity and to test the 
robustness of findings in light of process decisions.  Subgroup analyses were planned based on socio-
demographics, clinical characteristics concerning psychiatric health and characteristics associated with pain, 
opioid analgesic prescribing and vulnerability to opioid dependence.  Where sufficient data were available 
these analyses were undertaken.  Moderator variables were based on study design and risk of bias in 
individual studies.  Subgroups and moderator variables were entered into a meta-regression model 
(DerSimonian-Laird method).  Within the scope of the current review there were insufficient studies to 
undertake meta-regression with more than one subgroup/moderator variable in each analysis. 
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Results 
Study selection 
Electronic searches identified 6088 articles and a further 76 were identified through manual searches.  A total 
of 2721 duplicates were identified resulting in a total of 3443 articles retained for eligibility review.  Figure 1 
shows the total number of articles that underwent eligibility review, reasons for exclusions on full text review 
and the total number of articles retained for inclusion.  Data were extracted from 12 articles, involving a total 
of 310,408 participants. 
 
[INSERT FIGURE 1 AROUND HERE] 
 
As shown in Figure 1, following abstract screening, 3347 articles were excluded.   They were identified as 
ineligible for the following reasons: systematic reviews/no primary data (n=434); in vitro/animal models 
(n=524); focus on addicted populations (n=364); drug efficacy studies (n=828); and focus on pain-related 
outcomes only (n=1197). 
 
Study characteristics 
The characteristics of included studies are shown in Table 1.  Where incidence of opioid dependence or abuse 
was not the primary objective, or was not the sole primary objective, the study design was reported for the 
method used to obtain incidence data rather than the method used in the overall study.  One of the included 
studies26 included 16 participants and had an event rate of zero; however, this study was retained in the 
meta-analysis since our selected meta-analysis method has the capacity to apply an adjustment, known as a 
‘continuity correction’, to facilitate inclusion of zero-count studies.  A continuity correction involves adding a 
constant value to each of the cells in the contingency table.  In consequence, the event rate for this study 
was 0.029 (i.e. 2.9%) rather than zero.  This does, however, necessarily impact on the confidence interval, 
widening it substantially, and this can be seen in the main forest plot in Figure 2. 
[INSERT TABLE 1 AROUND HERE] 
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Risk of bias within studies 
Risk of bias within studies were undertaken at study level, rather than outcome level, and assessed using 
instruments designed by the National Institutes of Health (NIH).  All studies were identified as being of either 
‘good’ or ‘fair’ quality; none were excluded due to being of ‘poor’ quality. 
 
Synthesis of results 
Figure 2 shows the overall study effects and summary effect.  The study effect symbol sizes are representative 
of the weighted contribution of each study (i.e. the precision of each study). 
 
[INSERT FIGURE 2 AROUND HERE] 
 
The summary effect, the weighted mean of all studies using a random effects model, was 0.047 (95% CI = 
0.021-0.104), indicating that 4.7% of patients prescribed opioid analgesic therapy were associated with de 
novo diagnostic status for opioid dependence or abuse during the follow-up observation period.  The 
confidence interval suggests that the ‘true’ value of the pooled effect size lies within the range 2.1% to 10.4%.  
The included studies are listed in Figure 2 in chronological order of date of publication and there was no 
pattern associated with findings over time.  Substantial heterogeneity was identified in study effects 
(I2=99.78) [Q=4973 (df=11); p<0.001; Tau2=2.146 (SE=1.394; Variance=1.942; Tau=1.465)].  Heterogeneity 
was anticipated, and was examined further. 
 
Risk of bias across studies 
Assessment of risk of publication bias showed a fairly symmetrical distribution suggesting no significant 
publication bias.  This was confirmed by the Egger regression intercept (t=0.64; df=10; p=0.536) and the Begg-
Mazumdar rank correlation test (Tau=0.15; p=0.493). 
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Additional analyses 
Sensitivity analyses for overall heterogeneity of study effects 
Sensitivity analyses were undertaken with two moderator variables (study design; and risk of bias in 
individual studies) and three subgroup variables (diagnostic criteria for identifying dependence or abuse; 
strength of analgesic opioid; and duration of opioid exposure).  Moderator and subgroup variables were 
entered into regression models, in an effort to explain the overall variance in study effects, and the results 
of significant models were reported in tables. 
 
Pooled effect estimates of incidence of iatrogenic opioid dependence or abuse did not differ significantly by 
study design (p=0.432).  Cross-sectional study designs generated a pooled effect of 4.7%; pre-post study 
designs generated a pooled effect of 10.7%; and prospective cohort study designs generated a pooled effect 
of 1.7%.  Meta-regression generated a non-significant model. 
 
Pooled effect estimates of incidence of iatrogenic opioid dependence or abuse differed significantly by risk 
of bias within studies (p=0.024).  Studies identified as being of ‘fair’ quality generated a pooled effect of 
15.1% whilst studies identified as being of ‘good’ quality generated a pooled effect of 3.1%.  Meta-regression 
generated a non-significant model. 
 
Pooled effect estimates of incidence of iatrogenic opioid dependence or abuse differed significantly by 
diagnostic criteria for identifying dependence or abuse (p<0.001).  There were, however, two single-sample 
groups – one study using both DSV-IV and ICD-9 criteria generated an effect of 2.9% and one study using 
clinician assessment generated an effect of 34.2%.  These two single-sample groups were removed and the 
data were reanalysed.  Findings are shown in Figure 3. 
 
[INSERT FIGURE 3 AROUND HERE] 
 
{ PAGE   \* MERGEFORMAT } 
 
As Figure 3 shows, pooled effect estimates of incidence of iatrogenic opioid dependence or abuse differed 
significantly by DSM-IV and ICD-9 diagnostic criteria for identifying dependence or abuse (p=0.002).   Studies 
which used ICD-9 criteria generated a pooled effect of 1.3% whilst studies which used DSM-IV criteria 
generated a pooled effect of 11.3%.  The meta-regression model was statistically significant (Q=7.77; df=1; 
p=0.005) and the results are shown in the supplementary material (Table 2).  The coefficient for the 
moderator variable was positive (+2.30), indicating that the use of DSM-IV diagnostic criteria was associated 
with more than twice the mean effect size of that of the reference category (i.e. ICD-9 criteria).  The meta-
regression showed that the inclusion of this moderator variable in the regression model explained 20% of 
the overall variance in study effects (R2=0.20). 
 
Pooled effect estimates of incidence of iatrogenic opioid dependence or abuse differed significantly by 
whether participants were in receipt of strong opioids, weak opioids or a mix of strong and weak opioids 
within individual study samples (p<0.001).  Studies where participants were prescribed strong opioids 
generated a pooled effect of 0.7%, studies where participants were prescribed weak opioids generated a 
pooled effect of 5.5% and studies where participants were prescribed a mix of strong and weak opioids 
generated a pooled effect of 6.1%.  Findings are shown in Figure 4.  Meta-regression generated a non-
significant model. 
 
[INSERT FIGURE 4 AROUND HERE] 
 
Pooled effect estimates of incidence of iatrogenic opioid dependence or abuse differed significantly by 
duration of exposure to opioid analgesics (p=0.020).  Studies where participants were prescribed opioids for 
3 months or more generated a pooled effect of 2.3% whilst studies where participants were prescribed 
opioids for a varied period of time generated a pooled effect of 10.7%.  Findings are shown in Figure 5.  The 
meta-regression model was statistically significant (Q=3.98; df=1; p<0.005) and the results are shown in the 
supplementary material (Table 3). 
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[INSERT FIGURE 5 AROUND HERE] 
 
The coefficient for the moderator variable was negative (-1.57), indicating that studies where participants 
were exposed to opioid analgesics for ≥3 months were associated with a mean effect size 1.57 times smaller 
(with the inverse of 1.57 being 0.66) than studies where participants underwent a mix of acute and chronic 
exposure.  The meta-regression showed that the inclusion of this moderator variable in the regression model 
explained 18% of the overall variance in study effects (R2=0.18). 
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Discussion 
Summary of evidence 
The current review is novel in examining the incidence (assumed to be new cases) – rather than prevalence 
(existing cases) – of iatrogenic opioid dependence or abuse following exposure to prescribed opioid 
analgesics.  Furthermore, the outcome measure focused on diagnostic status of dependence or abuse 
disorders, ensuring examination of debilitating problematic opioid use rather than focusing on aberrant drug-
related behaviour indiscriminately, which may include recreational use and other forms of non-problematic 
use.  Twelve studies were identified for inclusion in the meta-analysis, including 310,408 participants, and 
were of either ‘good’ or ‘fair’ quality.  The pooled incidence estimate was 4.7%, but substantial heterogeneity 
in study effect sizes was found with incidence ranging from 0.2% to 34.2%.  In an effort to explain the 
substantial heterogeneity, a number of sensitivity analyses were undertaken.  Studies rated as being of ‘good’ 
quality were associated with a significantly lower incidence (3.1%) than ‘fair’ quality studies (15.1%).  ICD-9 
diagnostic criteria were associated with a significantly lower incidence (1.3%) than DSM-IV criteria (11.3%) 
and this explained 20% of the heterogeneity in study effects.  Strong opioids were associated with a 
significantly lower incidence (0.7%) than either weak opioids (5.5%) or studies utilising a mix or strong and 
weak opioids (6.1%).  Studies in which participants were prescribed opioids for 3 months or more were 
associated with a significantly lower incidence (2.3%) than studies in which participants were prescribed 
opioids for a varied period of time (10.7%) and this explained 18% of heterogeneity in study effects.  
Indicators of potential publication bias were negative. 
 
Limitations 
Searches were restricted to English language text only.  The search term was broad; however, an 
exhaustive list of drug-related terminology was not included.  Whilst unlikely, it is possible that 
articles referring to, for example, ‘aberrant drug-related behaviour’, could have identified clinical 
status in samples or subgroups.  Although studies were each of reasonable quality, there was 
substantial heterogeneity found in study effects.  A range of study designs and settings were used, 
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population characteristics varied between studies and very few studies provided evidence of 
sufficient statistical power to detect significant effects.  Furthermore, most of the included studies 
provided insufficient homogenous data to facilitate appropriate subgroup analyses.  Ideally, future 
studies will utilise rigorous study designs that may be pooled to generate summary effects in future 
meta-analyses.  Furthermore, the importance of subgroup data should be recognised and future 
studies should include, if possible, subgroup analyses of the most pertinent socio-demographic and 
clinical characteristics. 
 
All required data for all included studies were obtained and no publication bias was identified, 
demonstrated by study effects being relatively symmetrically-distributed around the mean and non-
significant findings of statistical tests of publication bias.   As a result of the relatively small number 
of studies included, and the established observations to predictors ratio of 10:1, it was not possible 
to enter more than one explanatory variable into each meta-regression model and, therefore, it was 
not possible to derive complete models explaining heterogeneity.  Further studies are required to 
facilitate a robust evidence base that can effectively inform policy and practice in this important 
domain of health research. 
 
Comparison with other reviews 
The pooled incidence estimate of 4.7% is similar to the 3.3% incidence reported by Fishbain and colleagues8.  
They undertook a ‘structured evidence-based’ review of the incidence of opioid abuse/addiction.  They used 
a wider outcome definition (including addiction) than that of the current review; however, this finding shows 
that, irrespective of whether or not patients were associated with a clinical diagnosis of a dependence 
disorder, estimated incidence was similar. 
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The incidence reported by Noble and colleagues7 was considerably lower than the current finding; they 
reported signs of opioid addiction in 0.27% of pooled participants (and 0.14% in studies that did not refer to 
any previous history of substance misuse); however, due to the inclusion solely of case series in this part of 
their review, they were unable to compute a statistical pooled estimate of effect size using meta-analytical 
techniques.  Minozzi and colleagues9 undertook a qualitative synthesis of incidence of opioid dependence 
and reported an incidence range of 0 to 24% (with a median of 0.5%).  They did not, however, compute a 
pooled estimate of effect sizes.  Similarly, in a qualitative synthesis, Littlejohn and colleagues6 identified 
prevalence, as opposed to incidence, rates of up to 24% dependence and 41% abuse.  Furthermore, in the 
studies included by Littlejohn and colleagues, it was not made clear how the authors of included studies 
defined the varied terms that they used (dependence, withdrawal, addiction and abuse) and which, if any, 
indicated a clinical diagnosis.  Despite examination of a similar question, the findings of these three reviews 
are not comparable to the current review in terms of outcome measures and statistical techniques.  The 
calculation of averages and total percentages cannot take account of within-study variance in pooling 
methods and, in consequence, will generate relatively unreliable event rates. 
 
In the remaining review10, some of the included studies provided a single rate of misuse or addiction whilst 
others reported a range.  To ensure synthesis of the full complement of studies, the authors of this review 
calculated both a minimum and a maximum rate and, where a single value was reported in studies, this value 
was used to represent both the minimum and the maximum.  Whilst the reported prevalence rates of 
addiction are similar to the summary effect reported in the current review (4.3% and 4.7%, respectively), the 
reported prevalence rates of misuse were dramatically higher (69.4% and 69.5%, respectively).  One 
explanation may be that Vowles and colleagues defined ‘misuse’ as opioid use contrary to directions 
irrespective of the presence of harm or adverse effects.  This definition could include a substantial proportion 
of people engaging in non-problematic substance use and patients seeking or obtaining effective pain relief.  
One additional potential reason for elevated rates may be that, similar to Littlejohn and colleagues, Vowles 
and colleagues examined prevalence (existing cases) – rather than incidence (new cases) – of non-medical or 
illicit substance use.  This would necessarily result in elevated rates, since this would include people whose 
{ PAGE   \* MERGEFORMAT } 
 
substance misuse preceded analgesic prescribing.  Additionally, from a translational perspective, 
examination of prevalence rates cannot contribute effectively to an understanding of the development of 
dependence disorders following analgesic prescribing. 
 
Sensitivity analyses indicated a significantly lower incidence in studies that diagnosed dependence disorders 
in accordance with ICD-9 criteria as compared with DSM-IV criteria.  It is generally accepted that ICD criteria 
are typically somewhat more stringent than respective DSM criteria in producing a clinical diagnosis of many 
mental and behavioural disorders; it is, therefore, not surprising that a significantly lower incidence is 
associated with ICD-9 diagnostic criteria.  Subgroup analyses also indicated a significantly lower incidence 
associated with strong opioids and longer-term analgesic prescribing.  If the development of opioid 
dependence disorders is less likely in patients prescribed strong opioids in the longer term, this may suggest 
a mediatory role of pseudoaddiction, whereby patients in receipt of inadequate analgesia (weak opioids 
prescribed over short-term periods) exhibit addiction-like behaviour in an effort to achieve successful pain 
management.  We note that there may be other potential explanations of these counter-intuitive findings, 
such as differences in aetiology, pain severity or the nature of the pain; however, examination of these 
potential explanations goes beyond the scope of the present review. 
 
Conclusions 
The incidence of opioid dependence or abuse associated with analgesic prescribing identified in the 
current review was 4.7%.  Rates were lower among those with longer-term prescribing (>3 months) 
and those receiving strong rather than weak opioids.  This suggests a more modest direct effect of 
opioid analgesic prescribing, even in the longer term, than is generally perceived on the 
development of dependence or abuse.  It is beyond the scope of the present review to examine 
potential explanations of this finding.  It remains important to note, and aim to prevent, this serious 
adverse effect, and we have identified and quantified some key relevant factors.  There is a need 
for well-designed, rigorously-controlled, adequately-powered, prospective experimental studies 
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examining the incidence – rather than prevalence – of iatrogenic opioid dependence and abuse 
following analgesic prescribing.  Consideration should be given to the commissioning of a 
prospective registry with robust follow-up, which would enable careful oversight of incidence rates 
and facilitate the development of preventative strategies.  Furthermore, funders and commissioners 
should consider the potential for future meta-analyses when reviewing the study design, 
terminology definitions, outcome measures and statistical power of proposed future studies. 
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Figure legends 
Figure 1: Eligibility screening procedures and the total number of articles included in the review, 
shown on the PRISMA four-phase flow diagram 
 
Figure 2: Meta-analysis (random effects model) of overall study findings of the incidence of iatrogenic opioid 
dependence or abuse.  Studies are reported by ascending year of publication 
Note: It is recognised that incidence cannot fall below zero; however, the company providing the CMA software (Biostat 
Inc.) confirmed that it is not possible to generate a scale that is not symmetrical around zero. 
 
Figure 3: Sensitivity analysis of the incidence of iatrogenic opioid dependence or abuse by DSM-IV and ICD-9 
diagnostic criteria for identifying dependence or abuse 
 
Figure 4: Sensitivity analysis of the incidence of iatrogenic opioid dependence or abuse by strength of 
prescription opioid analgesics 
 
Figure 5: Sensitivity analysis of the incidence of iatrogenic opioid dependence or abuse by length of exposure 
to opioid analgesics 
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Study name Statistics for each study Event rate and 95% CI
Event Lower Upper 
rate limit limit Z-Value p-Value
Adams (2006) 0.055 0.049 0.061 -51.192 0.000
Buse (2012) 0.166 0.143 0.191 -18.240 0.000
Cepeda (2013) 0.005 0.004 0.006 -74.328 0.000
Chabal (1997) 0.342 0.245 0.455 -2.705 0.007
Cowan (2002) 0.029 0.002 0.336 -2.436 0.015
Dersh (2008) 0.150 0.132 0.171 -22.512 0.000
Edlund (2007) 0.020 0.018 0.022 -66.821 0.000
Edlund (2010) 0.032 0.030 0.033 -128.818 0.000
Edlund (2014) 0.002 0.002 0.002 -118.020 0.000
Flemming (2008) 0.034 0.024 0.048 -18.263 0.000
Huffman (2013) 0.325 0.247 0.414 -3.750 0.000
Hylan (2015) 0.057 0.049 0.067 -34.150 0.000
0.047 0.021 0.104 -6.929 0.000
-0.50 -0.25 0.00 0.25 0.50
 
 
 
Group by
Diagnostic criteria
Study name Statistics for each study Event rate and 95% CI
Event Lower Upper 
rate limit limit Z-Value p-Value
DSM-IV Adams (2006) 0.055 0.049 0.061 -51.192 0.000
DSM-IV Buse (2012) 0.166 0.143 0.191 -18.240 0.000
DSM-IV Dersh (2008) 0.150 0.132 0.171 -22.512 0.000
DSM-IV Flemming (2008) 0.034 0.024 0.048 -18.263 0.000
DSM-IV Huffman (2013) 0.325 0.247 0.414 -3.750 0.000
DSM-IV 0.113 0.058 0.210 -5.528 0.000
ICD-9 Cepeda (2013) 0.005 0.004 0.006 -74.328 0.000
ICD-9 Edlund (2007) 0.020 0.018 0.022 -66.821 0.000
ICD-9 Edlund (2010) 0.032 0.030 0.033 -128.818 0.000
ICD-9 Edlund (2014) 0.002 0.002 0.002 -118.020 0.000
ICD-9 Hylan (2015) 0.057 0.049 0.067 -34.150 0.000
ICD-9 0.013 0.004 0.043 -6.870 0.000
Overall 0.066 0.037 0.118 -8.246 0.000
-0.50 -0.25 0.00 0.25 0.50
  
 
Group by
Opioid strength
Study name Statistics for each study Event rate and 95% CI
Event Lower Upper 
rate limit limit Z-Value p-Value
Mixed Buse (2012) 0.166 0.143 0.191 -18.240 0.000
Mixed Chabal (1997) 0.342 0.245 0.455 -2.705 0.007
Mixed Dersh (2008) 0.150 0.132 0.171 -22.512 0.000
Mixed Edlund (2007) 0.020 0.018 0.022 -66.821 0.000
Mixed Edlund (2010) 0.032 0.030 0.033 -128.818 0.000
Mixed Edlund (2014) 0.002 0.002 0.002 -118.020 0.000
Mixed Flemming (2008) 0.034 0.024 0.048 -18.263 0.000
Mixed Huffman (2013) 0.325 0.247 0.414 -3.750 0.000
Mixed Hylan (2015) 0.057 0.049 0.067 -34.150 0.000
Mixed 0.061 0.023 0.155 -5.168 0.000
Strong Cepeda (2013) 0.005 0.004 0.006 -74.328 0.000
Strong Cowan (2002) 0.029 0.002 0.336 -2.436 0.015
Strong 0.007 0.002 0.026 -7.273 0.000
Weak Adams (2006) 0.055 0.049 0.061 -51.192 0.000
Weak 0.055 0.049 0.061 -51.192 0.000
Overall 0.054 0.049 0.060 -51.871 0.000
-0.50 -0.25 0.00 0.25 0.50
 
 
 
Group by
3 months or more on opioids
Study name Statistics for each study Event rate and 95% CI
Event Lower Upper 
rate limit limit Z-Value p-Value
3 months or more Cepeda (2013) 0.005 0.004 0.006 -74.328 0.000
3 months or more Chabal (1997) 0.342 0.245 0.455 -2.705 0.007
3 months or more Edlund (2007) 0.020 0.018 0.022 -66.821 0.000
3 months or more Edlund (2010) 0.032 0.030 0.033-128.818 0.000
3 months or more Edlund (2014) 0.002 0.002 0.002-118.020 0.000
3 months or more Hylan (2015) 0.057 0.049 0.067 -34.150 0.000
3 months or more 0.023 0.007 0.070 -6.318 0.000
Varied Adams (2006) 0.055 0.049 0.061 -51.192 0.000
Varied Buse (2012) 0.166 0.143 0.191 -18.240 0.000
Varied Cowan (2002) 0.029 0.002 0.336 -2.436 0.015
Varied Dersh (2008) 0.150 0.132 0.171 -22.512 0.000
Varied Flemming (2008) 0.034 0.024 0.048 -18.263 0.000
Varied Huffman (2013) 0.325 0.247 0.414 -3.750 0.000
Varied 0.107 0.055 0.195 -5.863 0.000
Overall 0.071 0.040 0.123 -8.298 0.000
-0.50 -0.25 0.00 0.25 0.50
Table 1: Characteristics of included studies 
Author (year) Study design 
(location) 
Malignant/non-
malignant pain (N) 
Prescription opioid 
(minimum length of 
exposure) 
Event 
rate (%) 
Adams (2006)22 Prospective 
cohort (USA) 
Non-malignant (6243) Hydrocodone; 
tramadol (varied) 
5.5 
Buse (2012) 23 Cross-sectional 
(USA) 
Non-malignant (922) Any (varied) 16.6 
Cepeda (2013) 24 Prospective 
cohort (USA) 
Mixed (39,367) Any (12 months) 0.5 
Chabal (1997) 25 Cross-sectional 
(USA) 
Non-malignant (76) Any (6 months) 34.2 
Cowan (2002) 26 Pre-post (UK) Non-malignant (16) Any (varied) 2.9 
Dersh (2008) 27 Cross-sectional 
(USA) 
Non-malignant (1323) Any (not known) 15.0 
Edlund (2007) 28 Cross-sectional Non-malignant (15,160) Any (3 months) 2.0 
Edlund (2010) 29 Cross-sectional 
(USA) 
Non-malignant (46,256) Any (3 months) 3.2 
Edlund (2014) 30 Cross-sectional Non-malignant (197,269) Any (3 months) 0.2 
Flemming (2008) 31 Cross-sectional 
(USA) 
Mixed (904) Any (varied) 3.4 
Huffman (2013) 32 Pre-post (USA) Non-malignant (120) Any (not known) 32.5 
Hylan (2015) 33 Pre-post (USA) Non-malignant (2752) Any (6 months) 5.7 
 
Table 2: Random effects (DerSimonian-Laird) meta-regression of duration of logit event rate on the 
criteria used to diagnose dependence or abuse (DMS-IV compared with ICD-9) using a Z-distribution 
Covariate Coefficient SE 95% lower 95% upper Z value p value 
Intercept -4.3506 0.5815 -5.4902 -3.2109 -7.48 <0.0001 
DSM-IV 2.2962 0.8240 0.6812 3.9111 2.79 0.0053 
 
 
Table 3: Random effects (DerSimonian-Laird) meta-regression of duration of logit event rate on opioid 
analgesic exposure (≥3 months compared with varied duration of exposure) using a Z-distribution 
Covariate Coefficient SE 95% lower 95% upper Z value p value 
Intercept -2.1772 0.5709 -3.2962 -1.0582 -3.81 0.0001 
≥3 months -1.5727 0.7887 -3.1186 -0.0268 -1.99 0.0462 
 
 
